<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(5)</volume><submitter>Cheng M</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Somatostatin receptor (SSTR)-targeted positron emission tomography/computed tomography (PET/CT) imaging has risen to the forefront for neuroendocrine tumor (NET) detection and management, yet the variability of significant uptake variability (SUV) as a semiquantitative measure of disease detection and tumor response to treatment has not been fully explored.&lt;h4>Methods&lt;/h4>We assess the reproducibility and interscan variability of SUV metrics of normal tissue and NET in serial &lt;sup>68&lt;/sup&gt;Ga-DOTA-NOC and &lt;sup>68&lt;/sup>Ga-DOTA-TATE PET imaging to clinically monitor disease state. Eighty-one patients were enrolled in this retrospective study.&lt;h4>Results&lt;/h4>Both primary and metastatic hepatic lesions demonstrated SUV (SUV&lt;sub>mean&lt;/sub> 16.5±8.0). The median SUV&lt;sub>mean&lt;/s</pubmed_abstract><journal>Hepatobiliary surgery and nutrition</journal><pagination>654-661</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9577978</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Highly variable biodistribution of &lt;sup>68&lt;/sup>Ga labeled somatostatin analogues &lt;sup>68&lt;/sup>Ga-DOTA-NOC and &lt;sup>68&lt;/sup>Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.</pubmed_title><pmcid>PMC9577978</pmcid><pubmed_authors>Cheng M</pubmed_authors><pubmed_authors>Tann M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Highly variable biodistribution of &lt;sup>68&lt;/sup>Ga labeled somatostatin analogues &lt;sup>68&lt;/sup>Ga-DOTA-NOC and &lt;sup>68&lt;/sup>Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.</name><description>&lt;h4>Background&lt;/h4>Somatostatin receptor (SSTR)-targeted positron emission tomography/computed tomography (PET/CT) imaging has risen to the forefront for neuroendocrine tumor (NET) detection and management, yet the variability of significant uptake variability (SUV) as a semiquantitative measure of disease detection and tumor response to treatment has not been fully explored.&lt;h4>Methods&lt;/h4>We assess the reproducibility and interscan variability of SUV metrics of normal tissue and NET in serial &lt;sup>68&lt;/sup&gt;Ga-DOTA-NOC and &lt;sup>68&lt;/sup>Ga-DOTA-TATE PET imaging to clinically monitor disease state. Eighty-one patients were enrolled in this retrospective study.&lt;h4>Results&lt;/h4>Both primary and metastatic hepatic lesions demonstrated SUV (SUV&lt;sub>mean&lt;/sub> 16.5±8.0). The median SUV&lt;sub>mean&lt;/s</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-18T22:14:40.709Z</modification><creation>2025-04-07T10:03:31.755Z</creation></dates><accession>S-EPMC9577978</accession><cross_references><pubmed>36268247</pubmed><doi>10.21037/hbsn-21-554</doi></cross_references></HashMap>